值得注意的是，宜明昂科近日公告称，根据与Instil Bio的全资附属SYNBIOTX有关IMM2510及IMM27M的授权及合作协议，公司已自SynBioTx收取500万美元的近期付款，并已收取付款合共1500万美元。公司预计未来将收取不超过3500万美元余下潜在付款。据悉，宜明昂科是为数不多的同时拥有PD-(L)1, VEGF和CTLA-4三个靶点管线的创新药企。Yimingangco-B (01541) rose nearly 4% in the afternoon, as of press time, up 2.99% to HK$5.16, with a turnover of HK$58.8606 million.
According to the Wise Finance APP, Yimingangco-B (01541) rose nearly 4% in the afternoon, as of press time, up 2.99% to HK$5.16, with a turnover of HK$58.8606 million.
On the news front, Yimingangco announced a global registration strategy in collaboration with Instil for the PD-L1xVEGF dual-specificity antibody IMM2510/SYN-2510 to be used in first-line non-small cell lung cancer (NSCLC) and first-line triple-negative breast cancer (TNBC) chemotherapy. After positive concept validation data, the company and Instil may initiate a global joint chemotherapy randomized phase 3 combination trial for first-line non-squamous and squamous NSCLC and/or first-line TNBC treatment.
It is worth noting that Yimingangco recently announced that, under the authorized and cooperative agreement with Instil Bio's wholly-owned subsidiary SYNBIOTX for IMM2510 and IMM27M, the company has received a recent payment of $5 million from SynBioTx and has received a total payment of $15 million. The company expects to receive up to $35 million in additional potential payments in the future. It is reported that Yimingangco is one of the few innovative drug enterprises with pipelines targeting PD-(L)1, VEGF, and CTLA-4 simultaneously.
